Umeclidinium/Vilanterol (Anoro Ellipta) is classified as which type of inhaler?

Umeclidinium/Vilanterol, marketed as Anoro Ellipta, is classified as a Dry Powder Inhaler (DPI). This classification is significant because DPIs deliver medication in a powder form that is inhaled into the lungs. Unlike metered dose inhalers (MDIs), which use a propellant to deliver a specific dose of medication, DPIs rely on the patient's inhalation to draw the powder into their lungs.

Anoro Ellipta is designed to provide a consistent dose with each inhalation, making it effective for managing respiratory conditions like Chronic Obstructive Pulmonary Disease (COPD). The inhaler features a unique mechanism that optimizes the powder's dispersion, which is crucial for achieving the necessary therapeutic effects. This delivery system's ease of use and lack of need for coordination between actuation and inhalation makes it a convenient option for many patients.

Understanding the classification of inhalers, such as DPI, helps in recognizing their distinct properties and advantages in treating respiratory diseases effectively.